(Publicis Consultants | PR) Sanofi Pasteur, the vaccines division of the sanofi-aventis group, announced today that the US Food and Drug Administrationhas licensed pentacel, diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine.
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b.
Pentacel vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to fifth birthday).
Post new comment